These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 7798779)
21. The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988-2004. Paul M; Gafter-Gvili A; Leibovici L; Bishara J; Levy I; Yaniv I; Shalit I; Samra Z; Pitlik S; Konigsberger H; Weinberger M Isr Med Assoc J; 2007 Jun; 9(6):424-9. PubMed ID: 17642387 [TBL] [Abstract][Full Text] [Related]
22. Bacteremia in patients with febrile neutropenia after chemotherapy at a university medical center in Malaysia. Baskaran ND; Gan GG; Adeeba K; Sam IC Int J Infect Dis; 2007 Nov; 11(6):513-7. PubMed ID: 17459753 [TBL] [Abstract][Full Text] [Related]
23. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. Fleischhack G; Hartmann C; Simon A; Wulff B; Havers W; Marklein G; Hasan C; Bode U J Antimicrob Chemother; 2001 Jun; 47(6):841-53. PubMed ID: 11389117 [TBL] [Abstract][Full Text] [Related]
24. Episodes of fever and neutropenia in children with cancer in a tertiary care medical center in Turkey. Tezcan G; Kupesiz A; Ozturk F; Ogunc D; Gultekin M; Yesilipek A; Hazar V Pediatr Hematol Oncol; 2006; 23(3):217-29. PubMed ID: 16517538 [TBL] [Abstract][Full Text] [Related]
25. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patients. Miller JA; Butler T; Beveridge RA; Kales AN; Binder RA; Smith LJ; Ueno WM; Milkovich G; Goldwater S; Marion A Clin Ther; 1993; 15(3):486-99. PubMed ID: 8364941 [TBL] [Abstract][Full Text] [Related]
27. Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplants. Koya R; Andersen J; Fernandez H; Goodman M; Spector N; Smith R; Hanlon J; Cassileth PA Bone Marrow Transplant; 1998 May; 21(9):923-6. PubMed ID: 9613785 [TBL] [Abstract][Full Text] [Related]
28. Should vancomycin be used empirically in febrile patients with prolonged and profound neutropenia? Results of a randomized trial. Pico JL; Marie JP; Chiche D; Guiguet M; Andremont A; Lapierre V; Richet H; Tancrede C; Lagrange P; Hayat M Eur J Med; 1993 May; 2(5):275-80. PubMed ID: 8252157 [TBL] [Abstract][Full Text] [Related]
29. Antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med; 1987 Feb; 316(7):410-2. PubMed ID: 3543678 [No Abstract] [Full Text] [Related]
30. Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after high-dose chemotherapy and peripheral blood stem cell transplantation. Egerer G; Goldschmidt H; Salwender H; Hegenbart U; Ehrhard I; Haas R; Ho AD Int J Antimicrob Agents; 2000 Jul; 15(2):119-23. PubMed ID: 10854807 [TBL] [Abstract][Full Text] [Related]
31. Comparison of meropenem with ceftazidime as monotherapy of cancer patients with chemotherapy induced febrile neutropenia. Malik I; Shaharyar J Pak Med Assoc; 2002 Jan; 52(1):15-8. PubMed ID: 11963577 [TBL] [Abstract][Full Text] [Related]
32. Pharmacoeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients. Dranitsaris G; Tran TM; McGeer A; Narine L Pharmacoeconomics; 1995 Jan; 7(1):49-62. PubMed ID: 10155293 [TBL] [Abstract][Full Text] [Related]
33. Empiric monotherapy for febrile neutropenia--a randomized study comparing meropenem with ceftazidime. Lindblad R; Rödjer S; Adriansson M; Andreasson B; Bäckström B; Johansson P; Karlsson K; Rhedin C; Turesson I Scand J Infect Dis; 1998; 30(3):237-43. PubMed ID: 9790130 [TBL] [Abstract][Full Text] [Related]
34. [Empirical treatment of fever and neutropenia: rationalization of antimicrobial schemes in the patient with cancer]. Santos JI Bol Med Hosp Infant Mex; 1989 Dec; 46(12):759-60. PubMed ID: 2627270 [No Abstract] [Full Text] [Related]
36. Systematic reviews and meta-analysis of febrile neutropenia. Paul M; Leibovici L Mayo Clin Proc; 2005 Sep; 80(9):1122-5. PubMed ID: 16178491 [No Abstract] [Full Text] [Related]
37. Empiric antimicrobial therapy in the community hospital setting for the cancer patient with fever and neutropenia: the need for vigilance and attention to detail. Gallagher JG Recent Results Cancer Res; 1993; 132():89-96. PubMed ID: 8265874 [No Abstract] [Full Text] [Related]
38. Experience with ceftazidime parenteral-to-parenteral dosage stepdown in the empiric treatment of febrile neutropenia. Schwagly N; Frighetto L; MacDougall C; Jewesson P Pharmacotherapy; 1999 May; 19(5):641-7. PubMed ID: 10331828 [TBL] [Abstract][Full Text] [Related]
39. Pediatric patients who receive antibiotics for fever and neutropenia in less than 60 min have decreased intensive care needs. Salstrom JL; Coughlin RL; Pool K; Bojan M; Mediavilla C; Schwent W; Rannie M; Law D; Finnerty M; Hilden J Pediatr Blood Cancer; 2015 May; 62(5):807-15. PubMed ID: 25663663 [TBL] [Abstract][Full Text] [Related]
40. Fever and neutropenia: changing patterns of medical practice. Arceci RJ J Pediatr Hematol Oncol; 2000; 22(5):397. PubMed ID: 11037846 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]